LAG3 and breast cancer: Furthermore, synergy between an anti-LAG-3 mAb and IL-12 contributes to the increased efficacy of IL-12 immunotherapy in breast cancer, which is solely dependent on NK cells, suggesting that LAG-3 is applicable in not only T cell-mediated immunotherapies but also NK cell-mediated antimetastatic immunotherapies (98).